Dayton Payne, MD
Rheumatology · Hickory, NCNPI 1639121239
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,643 of the $9,772 with a category attached, or 88.4%. 33 manufacturers reported payments, led by Amgen at 28.9% of the total.
Across 491 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AbbVie$1K
- UCB, Inc.$922
- Johnson & Johnson$612
- Novartis$575
- Pfizer$507
- plus $3K from 27 others
Across 33 payments — averaging $27,584 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$780K
- Eli Lilly$122K
- Pfizer$8K
What the payments were for
- Speaking & faculty fees$3504%
- Travel & lodging$6216%
- Food & beverage$8,64388%
- Education$1582%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 120 | $2,828 |
| AbbVie | 68 | $1,424 |
| UCB, Inc. | 57 | $922 |
| Johnson & Johnson | 32 | $612 |
| Novartis | 29 | $575 |
| Pfizer | 34 | $507 |
| AstraZeneca(2 entities) | 26 | $468 |
| E.r. Squibb & Sons, L.L.C. | 21 | $435 |
| Lilly USA, LLC | 18 | $298 |
| Sanofi | 8 | $200 |
| Organon | 9 | $170 |
| GSK | 10 | $170 |
| Aurinia Pharma U.S., Inc. | 7 | $134 |
| Genentech USA, Inc. | 7 | $123 |
| Radius Health, Inc. | 5 | $107 |
| Sandoz | 5 | $105 |
| Mallinckrodt Hospital Products Inc. | 4 | $100 |
| ANI Pharmaceuticals, Inc. | 5 | $91 |
| Boehringer Ingelheim | 4 | $79 |
| Sobi, Inc | 3 | $69 |
| Actelion Pharmaceuticals US, Inc. | 2 | $57 |
| Scilex Pharmaceuticals Inc. | 2 | $49 |
| Octapharma USA, Inc. | 2 | $44 |
| Bristol Myers Squibb | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Merck | 2 | $26 |
| Boston Scientific | 1 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $19 |
| Pacira Therapeutics, Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $17 |
| Assertio Therapeutics, Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $12 |
| Zyla Life Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,772 in reported general payments places this provider in the 75th percentile of 210 rheumatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 121 | $964,983 |
| RinvoqUpadacitinib | 110 | $708,311 |
| Humira(Cf) PenAdalimumab | 60 | $676,548 |
| Humira PenAdalimumab | 37 | $509,873 |
| Xeljanz XrTofacitinib Citrate | 77 | $446,770 |
| EnbrelEtanercept | 53 | $383,446 |
| HumiraAdalimumab | 23 | $258,252 |
| Orencia ClickjectAbatacept | 28 | $160,569 |
| SimponiGolimumab | 25 | $151,030 |
| Cimzia (2 Pack)Certolizumab Pegol | 22 | $125,201 |
| XeljanzTofacitinib Citrate | 21 | $121,738 |
| Taltz AutoinjectorIxekizumab | 13 | $91,463 |
| BenlystaBelimumab | 14 | $67,226 |
| Actemra ActpenTocilizumab | 22 | $54,190 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 621 | $18,698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira | $1,424 | $966,563133 claims |
| AmgenEnbrel | $2,828 | $383,44653 claims |
| Johnson & JohnsonSimponi | $612 | $151,03025 claims |
| UCB, Inc.Cimzia (2 Pack) | $922 | $125,20122 claims |
| PfizerXeljanz | $507 | $121,73821 claims |
| GSKBenlysta | $170 | $67,22614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 210 rheumatology providers in North Carolina.
Other rheumatology in Hickory
- Gordon LamCharlotte$2.7M
- Ralph SnydermanDurham$1.3M
- Wendy SimmonsWilmington$462K
- Andrew LasterCharlotte$421K
- Ana RossRaleigh$417K
- Gwenesta MeltonFayetteville$410K
- Joseph ShanahanDurham$407K
- Jill ZouzoulasCharlotte$377K
- Jill VargoAsheville$245K
- Robert HolmesPollocksville$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.